Skip to main content
      RT @DrPetryna: #eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs

      Olga Petryna DrPetryna

      4 years 6 months ago
      #eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0
      RT @KDAO2011: I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to

      k dao KDAO2011

      4 years 6 months ago
      I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to navigate the meeting in between telehealth visits at my command center! @RheumNow https://t.co/aGDAr8PPkA
      RT @drdavidliew: Big one from plenary, new option in ANCA-associated vasculitis:
      avacopan (anti-C5a) vs prednisolone in

      David Liew drdavidliew

      4 years 6 months ago
      Big one from plenary, new option in ANCA-associated vasculitis: avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow
      RT @DrPetryna: #eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary e

      Olga Petryna DrPetryna

      4 years 6 months ago
      #eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
      RT @drdavidliew: You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities.

      These data b

      David Liew drdavidliew

      4 years 6 months ago
      You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities. These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data. We need steroid-sparing in PMR. OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV
      RT @hanadymanasfi: New #therapeutic strategies in #SLE management
      #EULAR2020 https://t.co/dhvTKd4EGB

      dr hanady manasfi hanadymanasfi

      4 years 6 months ago
      New #therapeutic strategies in #SLE management #EULAR2020 https://t.co/dhvTKd4EGB
      RT @drdavidliew: Does TCZ actually fix GCA?
      @nihrheumatology cohort w serial PET/CT q6m:
      FDG uptake (PETVAS) reduces lon

      David Liew drdavidliew

      4 years 6 months ago
      Does TCZ actually fix GCA? @nihrheumatology cohort w serial PET/CT q6m: FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation Ongoing reductions in year 2? GCA doesn't sleep. @KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
      RT @Janetbirdope: Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than oth

      Janet Pope Janetbirdope

      4 years 6 months ago
      Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
      RT @drdavidliew: Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induct

      David Liew drdavidliew

      4 years 6 months ago
      Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induction: during maintenance following remission, it might predict relapse and renal decline independently of disease characteristics MAINRITSAN data OP0031 #EULAR2020 @RheumNow https://t.co/ItI0BPGrUX
      RT @KDAO2011: #EULAR2020 OP0167 Results are finally in!!
      MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonbl

      k dao KDAO2011

      4 years 6 months ago
      #EULAR2020 OP0167 Results are finally in!! MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
      RT @drdavidliew: So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany.

      German

      David Liew drdavidliew

      4 years 6 months ago
      So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany. Germany can come to me! Just getting into the #EULAR2020goesvirtual spirit @RheumNow https://t.co/RxeTwunR0K
      When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020

      Dr. John Cush RheumNow

      4 years 6 months ago

      When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020

      ×